KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Total Current Liabilities (2016 - 2025)

Neogenomics (NEO) has disclosed Total Current Liabilities for 16 consecutive years, with $88.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 70.69% year-over-year to $88.3 million, compared with a TTM value of $88.3 million through Dec 2025, down 70.69%, and an annual FY2025 reading of $88.3 million, down 70.69% over the prior year.
  • Total Current Liabilities was $88.3 million for Q4 2025 at Neogenomics, down from $97.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $301.2 million in Q4 2024 and bottomed at $67.8 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $129.4 million, with a median of $92.8 million recorded in 2021.
  • Peak annual rise in Total Current Liabilities hit 264.61% in 2025, while the deepest fall reached 70.69% in 2025.
  • Year by year, Total Current Liabilities stood at $87.2 million in 2021, then rose by 3.1% to $89.9 million in 2022, then grew by 7.09% to $96.3 million in 2023, then soared by 212.8% to $301.2 million in 2024, then plummeted by 70.69% to $88.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for NEO at $88.3 million in Q4 2025, $97.9 million in Q3 2025, and $100.1 million in Q2 2025.